Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1157]

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or...

Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

Dr Julie Graff - Oregon Health & Science University, Portland, USA

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )

BCG dosing for bladder cancer: Standard frequency schedule correct

Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany

BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC ( Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA )

Integrative molecular characterisation of S/R RCC to reveal determinants of...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally...

Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )

OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients

Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec

OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients ( Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec )

ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and...

Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob

ASCO GU 2020: Bladder: Genomic profiling, real-world treatment challenges and novel agents ( Dr Petros Grivas, Dr Shilpa Gupta, Dr Alison Birtle and Dr Joseph Jacob )

Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer

Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston...

Sitravatinib and nivolumab combo for advanced clear cell renal cell cancer ( Dr Pavlos Msaouel - The University of Texas MD Anderson Cancer Center, Houston, USA )

BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant...

Dr Shilpa Gupta - Case Comprehensive Cancer Center, Cleveland, USA

BLASST-1: Combining nivolumab, gemcitabine and cisplatin for the neoadjuvant treatment of muscle invasive bladder cancer ( Dr Shilpa Gupta - Case Comprehensive Cancer Center, Cleveland, USA )

More from ecancer